Growth Hormone · 10mg × 10 vials
GHRH analog + ghrelin mimetic in one vial. The classic pairing studied for amplified pulsatile GH release.
CJC-1295 and ipamorelin act on two separate growth-hormone pathways that converge at the pituitary, which is why they are studied together. CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH 1-29) modified to resist enzymatic breakdown. It binds the GHRH receptor on pituitary somatotrophs and raises the amplitude of each GH pulse the pituitary is primed to release. Ipamorelin is a five-amino-acid growth hormone releasing peptide that binds the ghrelin receptor (GHS-R1a) and triggers the pulse itself.
GHRH alone raises the amplitude of natural pulses; a GHRP alone triggers additional pulses at whatever amplitude baseline GHRH tone allows. When both receptors are engaged at once, the resulting GH pulse is substantially larger than the sum of the parts, the synergy first described by Bowers in 1991. Downstream, the larger pulse drives hepatic IGF-1 production.
Two forms of CJC-1295 exist and are not interchangeable. CJC-1295 without DAC (modified GRF 1-29) has a half-life of about 30 minutes and produces a short GH pulse that mirrors natural physiology. CJC-1295 with DAC carries a maleimido-lysine group that covalently binds serum albumin, extending the half-life to 6 to 8 days and producing sustained rather than pulsatile elevation. Ipamorelin's distinguishing property, established in the 1998 Raun et al. swine study, is selectivity: it released GH with potency comparable to GHRP-6 without raising ACTH, cortisol, or prolactin even at 200 times the GH ED50.
What the published studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
landmark CJC-1295 with-DAC pharmacokinetics, 5.8-8.1 day half-life, 2-10x GH elevation, 1.5-3x IGF-1 elevation
Read study ↗PubMedRaun K, Hansen BS et al, Ipamorelin, the first selective growth hormone secretagogue, Eur J Endocrinol 1998, 139(5):552-561:552-561](https://academic.oup.com/ejendo/article-abstract/139/5/552/6748390) - defining selectivity paper, ipamorelin releases GH at potencies similar to GHRP-6 without ACTH, cortisol, prolactin, FSH, LH, or TSH elevation even at 200x ED50
Read study ↗PubMedBowers CY, GHRH and GHRP synergy on GH releaseoriginal synergy demonstration showing co-administration produces GH response exceeding the sum of either alone (1991 framework, broadly cited)
Read study ↗PubMedSackmann-Sala L et al, A mechanistic view of growth hormone signaling pathwaysGHRH/GHRP receptor pathway separation framework
Read study ↗Clinical guidelinesCJC-1295 with-DAC complete research guide, Your Peptide Brand 2026synthesis of pharmacokinetics, RCT data, DAC mechanism
Read study ↗Clinical guidelinesCJC-1295 with-DAC vs without-DAC pharmacokinetic comparison, Particle PeptidesRead study ↗Storage: refrigerated, ~30 days after reconstitution. Unreconstituted vials stable at room temp short-term, refrigerate long-term. Don't freeze reconstituted vials.